COMP <GO>
KEQU vs MRK // RSI-14 & 200D SMA MOMENTUM
Kewaunee Scientific Corporation (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: KEQU 5
— MRK 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MRK
LAST: $33.44 (-0.21%) • MKT CAP: $97.0M
rsi-technicals
49.8
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
rsi-technicals
51.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KEQU VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KEQU | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.50% | 74.80% | -46.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.70% | 20.70% | -4.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.3x | 15.3x | -9.00 | KEQU | /valuation <GO> |
| Free Cash Flow Yield | 19.20% | 3.42% | +15.78 | KEQU | /fcf-yield <GO> |
| Operating Margin | 5.90% | 34.30% | -28.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 28.10% | -24.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 17.30% | 1.30% | +16.00 | KEQU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.37 | 5.19 | -1.82 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | KEQU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 49.8 | 51.7 | -1.90 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 18.4x | -9.90 | KEQU | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $97.0M | $361.02B | -$360.92B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KEQU REV | MRK REV | KEQU GROSS % | MRK GROSS % | KEQU FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $282.0M | $65.01B | 28.5% | 74.8% | $18.6M | $12.36B |
| FY 2024 | $240.5M | $64.17B | 28.6% | 76.3% | $14.8M | $18.10B |
| FY 2023 | $203.8M | $60.12B | — | — | $19.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KEQU // BETA —
MRK // BETA 0.92